Stephan Rosenfeld, MD
Hematology & Oncology · Fayetteville, ARNPI 1083685283
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $50,065 of the $61,437 with a category attached, or 81.5%. Daiichi Sankyo Inc. accounts for 66.5% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2020 at $23,005 and has fallen 79.5% since, to $4,713 in 2025. Among hematology & oncology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 549 payments — averaging $111.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$41K
- AstraZeneca$8K
- Pfizer$1K
- Seagen Inc.$1K
- Incyte Corporation$956
- Johnson & Johnson$770
- plus $8K from 54 others
What the payments were for
- Consulting fees$50,06581%
- Speaking & faculty fees$2,4854%
- Travel & lodging$6761%
- Food & beverage$7,67012%
- Education$5401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,437 in reported general payments places this provider in the 95th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 142 | $2,255,510 |
| ImbruvicaIbrutinib | 43 | $703,682 |
| IdhifaEnasidenib Mesylate | 16 | $561,970 |
| CalquenceAcalabrutinib Maleate | 33 | $497,371 |
| InlytaAxitinib | 20 | $488,108 |
| TukysaTucatinib | 19 | $400,848 |
| OrserduElacestrant Hcl | 16 | $374,717 |
| Imatinib Mesylate | 20 | $34,257 |
| EliquisApixaban | 30 | $20,572 |
| XareltoRivaroxaban | 17 | $15,119 |
| Letrozole | 535 | $10,172 |
| Tamoxifen Citrate | 118 | $2,804 |
| Prochlorperazine Maleate | 51 | $1,379 |
| Anastrozole | 54 | $1,355 |
| Ondansetron OdtOndansetron | 69 | $1,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Inlyta, Eliquis | $1,447 | $2,764,189192 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $100 | $703,68243 claims |
| Bristol Myers SquibbIdhifa | $100 | $561,97016 claims |
| AstraZenecaCalquence | $8,214 | $497,37133 claims |
| Seagen Inc.Tukysa | $1,168 | $400,84819 claims |
| Stemline Therapeutics Inc.Orserdu | $103 | $374,71716 claims |
| Johnson & JohnsonXarelto | $770 | $15,11917 claims |
| Lilly USA, LLCOlanzapine | $113 | $6313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Fayetteville
- Eric SchaeferFayetteville$466K
- Patrick TravisFayetteville$37K
- Joseph BeckFayetteville$22K
- Gregory OakhillFayetteville$9K
- Matthew LockwoodFayetteville$8K
- K'anne ArthurFayetteville$8K
- Lynsay BrautnickFayetteville$7K
- Brooke BranderFayetteville$6K
- Mitchell RossFayetteville$3K
- Frits van RheeLittle Rock$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.